Why Precision Medicine?


A 2016 study showed that the percentage of cancer patients who achieved tumor shrinkage doubles when prescribed treatments matched to their genomic profile (32% vs 62%).

Comprehensive genomic profiling enables physicians to select the most suitable treatment and find more treatment options based on each patient’s genomic characteristics. Using ACTOnco®+ comprehensive genomic profiling, 83.9% of the patients found treatment solutions that correspond to their genomic profile.


% Achieved Tumor Shrinkage

Conventional Medicine

Precision Medicine
Genotype-matched and personalized

Source: Genome Medicine (2016) 8:109

What We Offer

Comprehensive Genomic Profiling

ACTOnco®+ analyzes 440 genes to assist physicians in finding more treatment options and identifying the most suitable therapies. Treatment evaluation includes targeted therapy, immunotherapy, hormonal therapy and chemotherapy.

Liquid Biopsy for Cancer Monitoring

ACTMonitor™analyzes tumor DNA circulating in blood stream to provide physicians with real-time monitoring of drug resistance, early detection of cancer recurrence and evaluation of treatment responses.

Patient Stories

To date I have done three rounds of Genomic Profiling Analysis semi-annually to monitor my liver tumor genes mutation activities. In case I have a recurrence, or develop a secondary cancer, I will stand a better chance to treat it at early stage.


Andrew Tay, MD
A liver cancer survivor in Singapore

More Patient Stories

About ACT Genomics

ACT Genomics empowers physicians with evidence-based genomic insights and partners with biopharma to accelerate drug development through biomarker discovery, patient stratification and comprehensive cancer molecular analysis. We are headquartered in Taiwan with offices in Singapore, Hong Kong and Japan.


Found Treatment Solutions

Collaborating Hospitals

Biopharma & Research Partners



May 05-06 Novel treatment strategies in precision cancer medicine in TJCC

ACT Genomics invites the Deputy Director of Tokyo Medical and Dental University Cancer Center, Dr. Sadakatsu Ikeda as guest speaker and the Director of National Taiwan Hospital Graduate Institute of Oncology, Dr. James Chih-Hsin Yang as moderator to share

Get to know more about ACT Genomics



ACT Genomics May Enewsletter

2018 VOL.05

See More

Keep in Touch

Subscribe to ACT Genomics Newsletter to be connected to the latest precision medicine